Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2026
This article has no abstract
Epistemonikos ID: f3faaa1862c15d3cd72a06f6a4ce8ac9387dbaaa
First added on: Aug 04, 2026